Editorial Comment to Does histologic subtype impact overall survival in observed T1a kidney cancers compared with competing risks? Implications for biopsy as a risk stratification tool

Affiliations

Editorial

Kiyoshi Takahara et al. Int J Urol. 2022 Aug.

. 2022 Aug;29(8):851-852.

doi: 10.1111/iju.14947. Epub 2022 Jun 8.

¹ Department of Urology, School of Medicine, Fujita Health University, Toyoake, Aichi, Japan.

No abstract available

Comment on

Does histologic subtype impact overall survival in observed T1a kidney cancers compared with competing risks? Implications for biopsy as a risk stratification tool.
Michael J, Velazquez N, Renson A, Tan HJ, Rose TL, Osterman CK, Milowsky M, Kang SK, Huang WC, Bjurlin MA. Michael J, et al. Int J Urol. 2022 Aug;29(8):845-851. doi: 10.1111/iju.14910. Epub 2022 Apr 26. Int J Urol. 2022. PMID: 35474518

1. Pierorazio PM, Johnson MH, Ball MW et al. Five-year analysis of a multi-institutional prospective clinical trial of delayed intervention and surveillance for small renal masses: the DISSRM registry. Eur. Urol. 2015; 68: 408-15.
1. Smaldone MC, Kutikov A, Egleston BL et al. Small renal masses progressing to metastases under active surveillance: a systematic review and pooled analysis. Cancer 2012; 118: 997-1006.
1. Nguyen DP, Vertosick EA, Corradi RB et al. Histological subtype of renal cell carcinoma significantly affects survival in the era of partial nephrectomy. Urol. Oncol. 2016; 34: e1-8.
1. Yoo S, You D, Jeong IG et al. Histologic subtype needs to be considered after partial nephrectomy in patients with pathologic T1a renal cell carcinoma: papillary vs. clear cell renal cell carcinoma. J. Cancer Res. Clin. Oncol. 2017; 143: 1845-51.
1. Michael J, Velazquez N, Renson A et al. Does histologic subtype impact overall survival in observed T1a kidney cancers compared with competing risks? Implications for biopsy as a risk stratification tool. Int. J. Urol. 2022; 29: 845-51.